Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.
Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
